initi coverag
momentum balanc high expect
launch coverag neutral rate price target
given recent share perform rais expect see risk upsid
modestli ahead downsid risk stage growth consensu
bake growth actual think
look low base recent momentum ahead year despit
struggl valuat sale one highest multipl growth
med-tech stage view cgm market strong rise tide also
concern tail risk lower cgm price/reimburs
balanc enthusiasm product execut
cgm market grow back ub evid lab survey
analysi ub evid lab diabet survey plural physician patient
call annual growth cgm volum next two year compani
project patient survey express high satisfact current cgm
good insur coverag despit patient appear unhappi diabet
cost physician survey specul could price/reimburs cut
like grow cgm market rate
physician survey view likeliest share gainer next
year given cost advantag libr compani reput servic
fewer physician saw share gainer posit good accuraci
calibr slightli outweigh neg price prefer
guardian pick best overal technolog follow
survey also show rel high devic sticki among cgm user
switch gain patient
valuat price base sale
trade revenu rebound trough year ago
back sever quarter strong growth peer similar
growth reflect good market exposur lead product execut
struggl see signific upsid growth like deceler tough comp
trade data key metric
compani account thomson reuter ub estim metric mark ub analyst adjust appli valuat base averag share price year base
share price estimate
report prepar ub secur llc except core rate band page analyst certif
requir disclosur begin page ub seek busi compani cover research
report result investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
ub research thesi map guid think report
 us cgm market grow high twenti next two year
ye ub evid lab diabet survey plural call growth us cgm market
next two year versu compani estim us consensu growth
 dexcom grow cgm market rate
data say necessarili bad thing market growth robust ub
evid lab survey suggest like gain share vote
physician respond respect note grow smaller cgm base
like consensu view
 risk cgm price reimburs player enter market
unclear patient survey unhappi diabet cost physician seem think could
price/reimburs cut competit price cut payer gener
desir pay less thing think market bake lsd pressur
neutral rate base view strong product growth momentum
healthi cgm market mostli reflect share sale see potenti upsid
consensu think buy side alreadi risk includ competit price cut
balanc enthusiasm busi level
analysi ub evid lab diabet survey plural physician patient suggest cgm
market growth compani project high like
gain share rank well overal technolog vector like accuraci eas
use patient gener happi cgm devic
share re-rat revenu vs trough year ago follow sever
quarter acceler growth consensu estim call growth
upsid downsid
compani descript dexcom medic devic compani primarili focus design develop
commerci continu glucos monitor system use peopl diabet
initi coverag inc novemb
net share gains-to-loss estim cgm
physician rank best overal technolog
ev/sal rel
average rel
sourc exhibit compani data ub research
analysi ub evid lab survey result suggest
cgm volum grow next two year
pick gain share next two
year follow
trade revenu turn
three year averag
initi coverag inc novemb
order see whether thesi play here well track
next six month beyond
pilot activ
on-going partnership
gener devic
collabor verili
color pipelin partnership updat
analyst day agenda final
expect provid gener color pipelin long
term view busi interest us
partner verili patient
payer think modest posit
stock
revenu
typic announc preliminari sale result
initi outlook next year competitor
confer jan think meet
guidanc revenu consensu
model revenu
shift pharmaci channel dme put
pressur revenu per patient believ volum
increas broader patient access eventu
off-set drive solid revenu growth
begin use dispos variou
pilot activ beyond follow recent
clearanc devic peopl year
age expect dispos could valuabl
diagnost tool peopl without diabet
novo nordisk lilli partner
insulin pump/pen offer believ
integr system addit
track commerci releas
gener devic expect major
advanc new electron insert system
sensor develop gone well
continu expect commerci releas late
initi coverag inc novemb
receiv fda approv ce mark
approv late
factori calibr day use valid verif
launch remain track late earli commerci launch
hybrid close loop system
hybrid close loop system
receiv fda approv ce mark
factori calibr day use valid verif
launch remain track late earli commerci launch
hybrid close loop system
hybrid close loop system
us launch aid system
pilot program on-going
compani report ub research
initi coverag inc novemb
 us cgm market grow high
twenti next two year
ye continu glucos monitor cgm allow diabet patient
effect manag diseas improv outcom reduc relianc
finger stick expect combin increas patient awar
better insur coverag accur user-friendli devic
drive rapid market growth high rang
analysi ub evid lab diabet survey plural call
growth next year posit trend support strong
cgm market growth specif survey physician pcp
endocrinologist suggest annual growth cgm volum
next two year fuel patient volum growth increas cgm
penetr signific upsid current cgm penetr type
insulin intens type patient excit among physician
close loop system integr pump
believ could spur anoth wave market growth launch
increas cgm use cite biggest chang practic last
month addit patient survey highlight high patient satisfact
current use think bode well
reorder good insur coverag patient
respond least partial insur coverag
consensu like model cgm market growth line
expect laid analyst day june piec togeth street
estim diabet found consensu
model slower market growth
glucos monitor doubl tripl year
diabet patient volum grow year
cgm flash volum grow expens finger stick
physician see cgm libr use last month
high satisfact cgm bode cgm market expans
survey suggest insur coverag
initi coverag inc novemb
glucos monitor doubl tripl
diabet affect peopl global peopl us around
peopl diabet remain undiagnos us leav peopl
diagnos diabet diabet classifi type type
type diabet autoimmun disord typic develop
age character absenc insulin hormon type
diabet metabol disord character lack suffici insulin hormon
type patient requir daili rapid-act insulin subset
type patient sever diabet requir subset
known insulin intens type rest type patient manag
diseas life-styl chang oral medic long-act insulin
figur epidemiolog type diabet
bodi creat insulin
insulin resist cell
use insulin properli
typic age
typic appear late life
diet exercis
aprox
million use insulin
type insulin intens type patient constitut address
devic market diabet sinc diseas manag daili rapid-act
insulin either pump autom insulin deliveri multipl daili
inject mdi syring insulin pen global around
patient pump patient mdi us around
diabet patient use insulin pump type patient
figur continuum diabet mdi pump intensively-manag patient
type insulin intens type patient need frequent glucos monitor
part insulin treatment compar tradit self-monitor blood
glucos use finger stick devic continu glucos monitor cgm better
way monitor glucos level howev accord cgm
penetr among intens manag diabet patient us
believ penetr increas time
make cgm standard care glucos monitor outsid us
cgm penetr much lower europ far less asia
cgm integr pump autom insulin deliveri use
stand-alone guid time frequenc mdi estim
global cgm market grow
initi coverag inc novemb
system newest
gener continu glucos
monitor system peopl
diabet new featur
discreet low profil among
other approv
fda march
compani also expect cgm market doubl even tripl
consid gold standard cgm time
highli accur product recent launch next
gener version recent two competit cgm devic receiv
approv includ guardian connect us eu
abbot freestyl libr flash monitor system us consum
system eu next-gen libr devic option real-tim alarm
freestyl libr receiv ce mark approv octob although
late game share compani believ stand-alone guardian
connect cgm potenti increas market share
strong success libr system note patient global
use system countri make use cgm flash
monitor term total number patient
analysi ub evid lab diabet
devic survey endocrinologist
ub evid lab conduct on-line survey endocrinologist
primari physician regard use cgm insulin pump
diabet patient order particip survey pcp endo see
least diabet patient annual familiar patient
current use insulin pump
diabet patient volum grow
respond treat averag diabet patient annual
today expect averag increas next two year
repres two-year compound-annual-growth-rate look sub categori
largest patient volum increas come insulin intens type
physician respond see averag patient today expect
grow next two year compound-annual-growth-rate insulin intens
type current repres diabet patient volum today
expect make patient volum two year
time type non-insulin intens type patient expect
increas respect percentag
mix two year
initi coverag inc novemb
figur overal diabet patient volum increas
year
ub evid lab physician survey question ask physician mani patient treat
annual today expect treat two year
cgm penetr rise percentag point year
averag use type patient insulin
intens type patient physician respond treat nation
averag among intens manag patient cite
time physician highlight broader patient use cgm
practic today widen scope includ flash monitor
freestyl libr doctor highlight
broader patient use today show impact
abl libr less year us market
physician respond expect cgm penetr increas
type patient make cgm prefer monitor devic
patient popul tradit finger stick flash monitor
flash monitor also grow averag group
respond also expect cgm penetr increas insulin
intens type patient flash monitor
type patient flash monitor across three patient
group cgm expect increas term percentag gain
flash monitor also increas across board
cgm remain prefer monitor devic type patient
physician respond see higher adopt flash monitor
freestyl libr cgm among type patient
initi coverag inc novemb
figur cgm gain share type insulin intens type patient
patient use flash monitor cgm tradit strips/stick
today estimate year
year
year
year
ub evid lab diabet physician survey question ask physician percentag patient use pump mdi insulin today two
cgm flash volum grow expens
physician survey data impli cgm growth annual
next two year compound-annual-growth-rate estim combin result
question math base annual patient volum
increas cgm penetr across differ group expect
grow annual next two year among physician respond
use math survey impli slower compound-annual-growth-rate flash monitor
next two year growth estim may conserv
given survey conduct freestyl libr approv
europ real-tim alert alarm featur could expand market
initi coverag inc novemb
tradit finger stick expect remain flat base survey
data despit fast diabet market growth tradit finger stick lose
share glucos monitor method name flash monitor
net-net survey impli growth tradit finger stick much
declin use among type patient
figur tradit finger stick remain flat despit diabet market
signific runway cgm growth
ask physician respond percentag intens manag patient
truli need real-tim glucos data alert alarm well
serv flash monitor without real-tim glucos data overal doctor
highlight type patient may better serv
alarm alert patient could well serv flash
monitor like freestyl libr without alarm alert note
receiv approv freestyl libr eu like bring
us futur remov perceiv ceil libr
initi coverag inc novemb
figur doctor agre patient serv alarms/alert
patient truli need real-tim glucos data alert
alarm vs well serv flash monitor
patient truli need real-tim glucos data alert alarm
patient well serv flash monitor abbott freestyl libr
ub evid lab question ask percent patient think truli need real-tim glucos
data alarm alert come fulli function versu
percent patient well-serv flash monitor like abbott freestyl libr
base survey data significantli runway growth cgm
alert alarm among intens manag patient physician
respond think type insulin intens type patient
truli need real-tim alert alarm lot higher current cgm
penetr type doubl penetr insulin intens
type patient proport patient need real-tim glucos data
alarm alert lower type patient suggest limit
upsid adopt popul
reach least type
yr
patient
figur insulin
yr
patient
hand physician predict strong growth flash
monitor think mani intens patient better serv
devic real time alerts/alarm secur ce mark approv
next-gen freestyl libr devic real-tim alarm featur freestyl
libr octob potenti approv libr us could shift
wide flash monitor use intens manag patient
specif physician respond believ type insulin
intens type patient well-serv flash monitor without real-tim
alert although patient may chose libr regardless eas use low
cost compar libr current penetr type
insulin intens type respond practic type patient
figur type
patient accord physician
yr
patient
initi coverag inc novemb
could well serv flash monitor compar current
penetr indic growth potenti libr patient popul
figur flash monitor expect
grow patient despit lack
figur patient
yr
serv flash
yr
serv flash
figur libr may best suit
patient without alarms/alert
yr
serv flash
ask new diabet drug devic
excit physician respond overwhelmingli cite artifici
pancrea hybrid close loop system fulli close loop system
still year away think current system move closer full autom
gener anoth wave excit market increas uptak
type system close loop system offer promis greater eas
use autom feedback also potenti improv
outcom safeti diabet patient
although first approv hybrid close loop system us
recent launch system hybrid featur well
look forward work take system advanc hybrid
close loop fulli close loop system
investig close loop system integr
pump clinic trial beyond artifici pancrea physician respond
also excit mention eversens mention
omnipod high dose insulin user mention gener
answer call new technologies/devic versu drug practic
chang highlight strong technolog cycl current
initi coverag inc novemb
figur physician excit artifici pancrea fulli close loop system
physician see cgm libr use last
ask biggest chang practic last
month physician respond often cite increas use
one respond even transit insulin-tr patient
finger stick chang includ usag closed-loop
pump libr well improv insur coverag
figur physician excit artifici pancrea fulli close loop system
cgm use featur
analysi ub evid lab diabet
cgm infus patient survey
ub evid lab conduct on-line survey patient
insulin intens diabet current use cgm insulin pump understand
experi specif brand insulin pump includ
satisfact percept
features/benefit survey field august
initi coverag inc novemb
high satisfact cgm bode cgm
patient respond survey gener satisfi cgm
current use nearli half patient respond satisfi
current cgm dissatisfi proport
patient satisfi cgm similar among three major
cgm vendor see posit sign market growth high
satisfact equal high reorder rate mani patient
could becom long term lifelong custom
figur patient respond dissatisfi current cgm
satisfact current cgm compani use
ub evid lab diabet patient survey question ask patient satisfi
addit patient respond vote accuraci eas use price/out
pocket cost top reason choos cgm
figur accuraci eas use top reason choos cgm
import featur choos cgm
eas use
price/out
look feel patient
ub evid lab diabet patient survey question ask patient import featur
drill top three attribut use choos
accuraci patient rate current cgm good good eas
use cost/pric think squar well
initi coverag inc novemb
overal satisfact rate confirm patient like
continu use type devic
figur patient respond view cgm /veri eas use
patient rate cgm good/veri good across featur compani use
eas use
price/out pocket
look feel
ub evid lab diabet patient survey question ask patient rate cgm across featur benefit
survey suggest insur coverag
market access cgm product improv gain coverag
march unlock access medicar age patient repres
overal type market mani patient us
medicar age insulin intens type patient could even larger
opportun also achiev coverag freestyl libr januari
secur partial full reimburs coverag system countri
octob guardian connect yet
coverag requir confirmatori finger stick
view reimburs coverag import driver cgm market
growth given cgm expens compar test strip type
diabet tend skew toward lower social econom statu ub
evid lab diabet patient survey patient respond
receiv least partial insur coverag
nearli half patient respond fulli cover
among cgm vendor compar insur coverag
lower proport patient full insur coverag
initi coverag inc novemb
figur patient respond receiv insur coverag
proport patient health insur pay cgm
insur
cover
ye
cost
pocket cost high
ye
cost
ye cost
ub evid lab diabet patient survey question ask patient healthcar insur pay
cgm devic
sampl coverag appear broad-bas larg insur like
aetna bcb kaiser unit wellcar cover
sampl patient medicar advantag well
figur insur coverag appear broad base survey proport patient cite specif commerci
patient need pay someth pocket cash co-pay
deduct etc consid cost pay
high howev patient think cost extrem high
initi coverag inc novemb
figur pocket cgm consid high patient
percept oop cost paid among patient oop cost
ub evid lab diabet patient survey question ask patient describ cost pay
pocket cgm devic
around patient respond receiv financi incent
insur use percentag highest user
statist signific
figur around patient respond receiv incent use
patient whose insur offer incent use cgm
ub evid lab diabet patient survey question ask patient healthcar insur give
financi incent use cgm devic
initi coverag inc novemb
 dexcom grow cgm market rate
possibl rise tide still mean strong growth next
year start lower share posit stand-alone
strong hybrid close loop offer allow
grow market time libr seen fastest
growth uptak patient make outpac
market next gener product could begin encroach tradit
given addit alarm alert
ub evid lab diabet survey suggest like
gain share glucos monitor space specif survey
physician show likeliest share gainer doctor
cite cost advantag libr compani reput servic
vote share gainer fewer physician posit good
accuraci calibr slightli outweigh neg price
prefer guardian pick best overal
technolog among either stand-alone integr pump
follow vote best stand-alone cgm
bit surpris think may earli doctor
form opinion tndm/dxcm combin
receiv lot mention best new product addit patient survey
highlight rel high devic sticki among cgm user
use patient current sampl
consensu model revenu growth
respect compar expect market growth least
view like gain share
drew switch mostli test strips/oth
initi coverag inc novemb
analysi ub evid lab diabet
devic survey endocrinologist
ub evid lab conduct on-line survey endocrinologist
primari physician regard use cgm insulin pump
diabet patient order particip survey pcp endo see
least diabet patient annual familiar patient
current use insulin pump
view like gain share
physician ask predict compani would gain lose
share us market count net share gains-to-loss net net
physician respond expect gain market share cgm
space tabul percentag doctor chose gain
share next year minu percentag expect lose
share diffus index similarli net
result respect downsid
expect lose net market share
respect although believ neg vote may due
lack familiar product
figur physician vote compani gain share vote
lose share
net share gains-to-loss estim cgm
ub evid lab diabet physician survey question ask physician cgm manufactur
gain lose market share us next year
physician ask explain thought compani would gain
share next year receiv total share gain vote
versu tndm/
mention better cost coverag access eas
use smatter reason given comparison vote
share gain larg relat compani reput spread evenli across
categori vote relat safeti
accuraci sensor finger sticks/calibr
physician think gain share believ better
initi coverag inc novemb
figur cgm expect share gain relat coverag slant compani reput
eas use
stick
ask compani expect lose share cgm
segment receiv vote follow
note launch new integr product time
survey run may confus respond senseon chosen
frequent due lack familiar vote larger player
roughli equal
physician pick manufactur lose share come year
reason given low familiar smaller compani
includ prefer
wors technolog less accur reliabl
figur expect share loss relat familiar
physician feedback call mani factor contribut share gain
share gain share loss ratio posit
main reason expect share gain better price good
insur coverag eas use good product qualiti lower
accuracy/reli lack real-tim alerts/alarm wors technolog top
reason share loss note potenti us approv libr
real-tim alarm could skew percept posit net-
net view result posit
initi coverag inc novemb
eas use
ub evid lab physician survey question ask physician
cgm manufactur gain market share us next year
integr pump
ub evid lab physician survey question ask physician
cgm manufactur lose market share us next year
net score share gain versu share loss posit
side stood physician callout product qualiti
compani reput good market sale support fact
cgm integr pump also chart high convers
doctor like compani product found less
popular view respons posit
eas use
ub evid lab physician survey question ask physician
cgm manufactur gain market share us next year
ground lose
ub evid lab physician survey question ask physician
cgm manufactur lose market share us next year
total physician chose manufactur like
gain share common reason cite accuraci devic
make safe reliabl mention finger stick/calibr
featur second real-tim alarm featur mention
time better technolog call time good price/coverage/access
eas use also chart highli physician mention better
market note number mention sum total
physician cite multipl reason disaggreg flip side
physician pick lose market share cgm
space reason given convers top
reason chosen gain share poor price/coverage/access wors
technolog less user friendli less accurate/reli interestingli
physician mention lack popular cite fact cgm
integr pump like devic view respons
mix
initi coverag inc novemb
eas use
ub evid lab physician survey question ask physician
cgm manufactur gain market share us next year
integr pump
ub evid lab physician survey question ask physician
cgm manufactur lose market share us next year
tandem cgm combin share gains-to-loss
skew neg physician pick gain share
versu pick lose share posit cite better
technolog preference/popular top neg includ wors technolog
low familiar less market given tandem slim insulin pump
recent launch us august surpris low
familiar devic among physician respond physician gain
experi prescrib devic tandem may score higher time
view respons neutral
eas use
link insulin pump
ub evid lab physician survey question ask physician
cgm manufactur gain market share us next year
ub evid lab physician survey question ask physician
cgm manufactur lose market share us next year
result neg nine physician pick
gain share pick lose
physician cite low familiar low popular less market
physician mention invas devic reason share loss
view respons neg
ub evid lab physician survey question ask physician
cgm manufactur gain market share us next year
ub evid lab physician survey question ask physician
cgm manufactur lose market share us next year
initi coverag inc novemb
overal physician respond view guardian best
technolog despit guardian sensor view inferior
libr perceiv best stand-alone cgm devic follow
freestyl libr consid worst overal technolog
figur guardian view best overal technolog
physician rank best overal technolog
ub evid lab physician survey question ask physician rank cgm devic
individu assess accuraci eas use clinic benefit price
tie accuraci superior clinic benefit
vs unsurprisingli libr led pack eas use price follow
figur guardian tie
physician rank accuraci
ub evid lab physician survey question ask physician rank
figur libr view best eas use
physician rank eas use
ub evid lab physician survey question ask physician rank
initi coverag inc novemb
figur guardian view
physician rank clinic benefit
ub evid lab physician survey question ask physician rank
figur libr view best price
physician rank price
ub evid lab physician survey question ask physician rank
among new product approv last year physician
practic libr captur highest patient share follow
compar share vs vs despit
market month
follow guadian
mix cgm brand patient use
ub evid lab physician survey question ask physician
percent diabet patient current use product
mix cgm vendor patient use
ub evid lab physician survey question ask physician
percent diabet patient current use product
analysi ub evid lab diabet
cgm infus patient survey
ub evid lab conduct on-line survey patient
insulin intens diabet current use cgm insulin pump understand
experi specif brand insulin pump includ
satisfact percept
features/benefit survey field august
initi coverag inc novemb
drew switch mostli test
third patient respond switch current cgm
anoth glucos monitor product patient half
switch libr switch patient
switch libr like lower cost conveni lack alarms/alert
eight user switch test strip suggest libr may
drawn patient would otherwis use cgm better product
integr pump cite main reason switch
switcher quarter switch test strip
alreadi use cgm switch either upgrad
competit
figur patient switch product product
tslim
tandem tslim dexcom
know
ub evid lab diabet patient survey question ask patient product switch
potenti switcher mostli consid upgrad
ask think switch anoth cgm devic
next year less quarter patient respond said
ye patient consid upgrad leav
competit switch
patient third like switch
upgrad libr beyond libr
top devic current user consid switch surprisingli
patient think switch back test strip due
lower cost eas use top devic patient respond consid
switch libr
initi coverag inc novemb
figur patient like switch product product
tslim
tandem tslim dexcom
ub evid lab diabet patient survey question ask patient product like switch
takeaway patient survey worth highlight
nearli patient respond ask cgm brand instead
physician choos brand percentag
slightli higher
figur nearli patient respond ask cgm brand
person ask cgm brand
vs doctor choos brand
ub evid lab diabet patient survey question ask patient person ask doctor
prescrib cgm devic
around patient respond think real-tim alert
alarm featur extrem moder valuabl surprisingli
significantli higher proport user view alert featur
import interestingli half user believ alert
import use libr even though current
offer real-tim alert us
initi coverag inc novemb
figur patient respond think alert alarm featur
patient rate alert alarm
moderately/extrem valuabl cgm manufactur current
ub evid lab diabet patient survey question ask patient import featur
median sensor wear day mean day among
user survey around user survey would
use fewer sensor annual vs suggest could
econom patient recal longer sensor
wear wherea
figur would/wil use fewer sensor annual
vs
given shutoff would chang mani
sensor use annual among user
use sensor
annual
use
versu
annual
initi coverag inc novemb
 risk cgm price reimburs
player enter market
unclear stakehold specul lower price
freestyl libr could impact market price reimburs
seen hard evid stage least us
differ valu proposit libr versu expert
spoken believ deserv differenti reimburs despit
patient payer unhappi diabet cost physician survey
seem think could cut although sure base
fact reimburs cut like increas
half physician ub evid lab survey think libr could
pressur cgm price third think could neg impact
reimburs howev degre potenti price reduct clear
point patient ub evid lab survey rel unhappi
cgm cost around patient rate current cgm good
good price/out pocket cost vs accuraci eas
use patient least insur coverag
less half fulli cover cgm cost
full coverag consid pocket cost
high
think market bake lsd pressur
doc think libr could pressur cgm price reimburs
rel patient satisfact cgm cost despit
initi coverag inc novemb
doc think libr could pressur cgm price
half physician respond expect price cgm devic
pressur low cost libr although degre potenti price
reduct clear point
figur half physician expect libr
lead price reduct cgm devic
figur third expect reimburs
reduct cgm devic
rel patient satisfact cgm cost
patient survey vote price/out pocket cost third import reason
choos cgm howev patient rate current
cgm good good price/out pocket cost vs accuraci
eas use believ underscor patient respond
rel unhappi cgm cost
figur patient respond view cgm /veri eas use
patient rate cgm good/veri good across featur compani use
eas use
price/out pocket
look feel
ub evid lab diabet patient survey question ask patient rate cgm across featur benefit
despit low satisfact cgm cost ub evid lab survey suggest
good insur coverag specif patient
initi coverag inc novemb
respond receiv least partial insur coverag
nearli half patient respond fulli cover
figur patient respond receiv insur coverag
proport patient health insur pay cgm
insur
cover
ye
cost
pocket cost high
ye
cost
ye cost
ub evid lab diabet patient survey question ask patient healthcar insur pay
cgm devic
patient need pay someth pocket cash co-pay
deduct etc consid cost pay
high around patient think cost extrem high
figur pocket cgm consid high patient
percept oop cost paid among patient oop cost
ub evid lab diabet patient survey question ask patient describ cost pay
pocket cgm devic
around patient respond receiv financi incent
insur use percentag highest user
statist signific
initi coverag inc novemb
figur around patient respond receiv incent use
patient whose insur offer incent use cgm
ub evid lab diabet patient survey question ask patient healthcar insur give
financi incent use cgm devic
initi coverag inc novemb
think consensu number
look low
struggl valuat
consensu revenu look light base recent
pt base sale share
trade past year trade around midpoint
rang due solid quarterli result benefit upgrad
cycl adopt mdi look med-tech compani
grow revenu rang dxcm multipl top end
seen sever quarter strong revenu growth follow launch
sensor expans access us medicar ou coverag
think buy side like ahead street base stock momentum
note trade well regress line valuat versu growth
impli number
think deceler like given growth
show pharmaci channel headwind also drain point
benefit longer term despit sign ub evid lab survey
point strong continu growth market share gain
expect near term think cgm market rise
tide stage take patient away tradit finger stick
initi coverag inc novemb
trade revenu turn peak
trough late also turn
three year averag share re-rat due competit
launch reach bottom septemb follow fda approv
freestyl libr share recov sinc back sever quarter
strong financi result current premium versu
three year averag
ev/sal rel
average rel
initi coverag inc novemb
appear expens vs diabet high-growth name
pure-play name diabet space similar revenu growth
trade revenu two turn
higher revenu growth expect trade
view larger cgm player includ
appropri compar given much larger size slower growth leverag
market rel among high-growth small-cap name
averag ev revenu multipl
figur compar diabet small-cap med-tech growth name
ub research estim ratio base consensu number factset price
initi coverag inc novemb
figur revenu growth expect diabet peer high-growth name
ub research estim base consensu number factset
initi coverag inc novemb
show ev/revenu regress revenu growth us
small-cap name highest ev/revenu multipl farthest
revenu multipl growth trend line vs small cap comp
figur high valuat vs revenu growth compar peer
compani report ub research
initi coverag inc novemb
dcf show downsid current price base case wacc
termin growth termin margin reach
sale
sale
nopat
portion cf
tv
initi coverag inc novemb
upsid downsid
upsid upsid case assum achiev near growth
next two year impli minim price pressur factor
ebit margin also assum cgm market growth
base base case assum achiev growth
next two year assum slight price pressur factor ebit
margin cgm market growth high rang
downsid downsid case assum achiev high-teen
growth next two year impli moder price pressur factor
ebit margin cgm market growth
initi coverag inc novemb
revenu region
medic devic compani primarili focus
design develop commerci
continu glucos monitor system use peopl
diabet healthcar provid compani
three revenu compon sensor sale
headquart san diego california
receiv
particip diabet market provid
affect peopl global peopl
us diagnos diabet diabet classifi
type type us
type patient type
patient requir insulin type insulin intens
type patient need daili rapid-act insulin manag
diseas also need frequent glucos monitor
via either cgm finger stick part insulin
treatment global cgm market estim
grow
revenu product segment
initi coverag inc novemb
ub evid lab sell-sid team expert independ ub research work
across practic area special lab creat insight-readi dataset expert turn
data evid appli combin tool techniqu harvest cleans
connect billion data item month sinc ub research analyst util
expertis ub evid lab insight-readi dataset compani sector theme
result product differenti ub research report ub evid lab
provid research invest recommend advic provid insight-readi
dataset analysi ub research client
diabet devic survey endocrinologist
ub evid lab conduct on-line survey endocrinologist primari
physician regard use cgm insulin pump diabet patient order
particip survey pcp endo see least diabet patient annual
familiar patient current use insulin pump
diabet cgm infus patient survey
ub evid lab conduct on-line survey patient insulin intens
diabet current use cgm insulin pump understand experi specif
brand insulin pump includ satisfact percept cost switch
behavior import features/benefit survey field august
initi coverag inc novemb
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
initi coverag inc novemb
buy minor
revenu divis us
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
initi coverag inc novemb
valuat method risk statement
price target base revenu estim
risk price target includ slowdown cgm market
competit other price reimburs risk
regulatori risk around pipelin lack insur coverag
patient margin pressur cost inflat busi execut
low cost foreign competit foreign exchang
initi coverag inc novemb
